Labopharm To Pursue FDA Approval For Once-Daily Tramadol
This article was originally published in The Pink Sheet Daily
Executive Summary
As part of Ortho-McNeil's partnership with Biovail for extended release tramadol, Ortho is relinquishing exclusivity on the once-daily formulation - opening the way for Labopharm to pursue approval of its own product
You may also be interested in...
FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol
Cipher’s competing tramadol formulation has a user fee date more than a month ahead of the June deadline for Labopharm’s product.
FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol
Cipher’s competing tramadol formulation has a user fee date more than a month ahead of the June deadline for Labopharm’s product.
Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA
Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.